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Abstract
Background: Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for
11,000 deaths per year in the US. Approximately one-third of patients present with disease which is
already metastatic and for which there is currently no adequate treatment, and no biofluid screening tests
exist for RCC. In this study, we have undertaken a comprehensive proteomic analysis and subsequently a
pathway and network approach to identify biological processes involved in clear cell RCC (ccRCC). We
have used these data to investigate urinary markers of RCC which could be applied to high-risk patients,
or to those being followed for recurrence, for early diagnosis and treatment, thereby substantially reducing
mortality of this disease.
Results: Using 2-dimensional electrophoresis and mass spectrometric analysis, we identified 31 proteins
which were differentially expressed with a high degree of significance in ccRCC as compared to adjacent
non-malignant tissue, and we confirmed some of these by immunoblotting, immunohistochemistry, and
comparison to published transcriptomic data. When evaluated by several pathway and biological process
analysis programs, these proteins are demonstrated to be involved with a high degree of confidence (p
values < 2.0 E-05) in glycolysis, propanoate metabolism, pyruvate metabolism, urea cycle and arginine/
proline metabolism, as well as in the non-metabolic p53 and FAS pathways. In a pilot study using random
urine samples from both ccRCC and control patients, we performed metabolic profiling and found that
only sorbitol, a component of an alternative glycolysis pathway, is significantly elevated at 5.4-fold in RCC
patients as compared to controls.
Conclusion: Extensive pathway and network analysis allowed for the discovery of highly significant
pathways from a set of clear cell RCC samples. Knowledge of activation of these processes will lead to
novel assays identifying their proteomic and/or metabolomic signatures in biofluids of patient at high risk
for this disease; we provide pilot data for such a urinary bioassay. Furthermore, we demonstrate how the
knowledge of networks, processes, and pathways altered in kidney cancer may be used to influence the
choice of optimal therapy.
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While accounting for only 3% of cancer incidence and
mortality in the US, kidney cancer (renal cell carcinoma;
RCC) is the sixth leading cause of cancer death in the US.
Early diagnosis of kidney-localized RCC is associated with
a quite favorable prognosis (89%), but patients who have
this disease often present with few signs, symptoms, or
laboratory abnormalities and are frequently (~30%) diag-
nosed at the metastatic stage when the prospects for cure
are dismal (9%)[1]. The incidence of RCC in the US, as
well as its associated mortality rates, are increasing[2], and
the mortality rate has not improved significantly, most
likely because currently available therapies for metastatic
disease are relatively ineffective. Thus, novel and conven-
ient diagnostic tests for this disease which can be utilized
early in its course before metastasis, such as those which
utilize readily accessible biofluids, are clearly needed.
We and others have previously identified tissue markers of
RCC which have prognostic value [3-5], yet there are few
extant studies which define any diagnostic protein or
metabolite in RCC patient biofluids[6]. Due to its inti-
mate association with the principal biofluid, urine, kidney
cancer appears exceptionally well suited for studies to
identify tumor markers in this material. In this study, we
have undertaken a comprehensive computational analysis
of tissue proteomic data to discover pathways and net-
works involved in clear cell RCC (ccRCC) oncogenesis
and progression. Furthermore, using metabolomic analy-
sis, we provide evidence in the urine of alterations in
those pathways which we have identified, constituting a
first step towards elucidation of an urinary "metabolic sig-
nature" of ccRCC which will prove useful for kidney can-
cer diagnostic testing of high risk patients in the clinic.
Our finding of striking homogeneity among the samples
evaluated based on statistical analysis suggests the feasi-
bility of using relatively low sample numbers in future
ccRCC proteomic analyses.
Results
Proteomic analysis of clear cell RCC tissue
Both tumor and adjacent normal (generally cortical) tis-
sue from the same kidney was obtained from four patients
(eight samples total) who had undergone nephrectomy
for renal masses and had the histological diagnosis of
clear cell RCC. The distribution was two male patients
with tumor grades 1 and 2, stage I and two female patients
with tumor grade 2, stages II and III; age ranges were from
32 to 79 years old. Only TNM staging and tumor grade
were available for all tissues. Despite these differences in
grade and stage, subsequent proteomic analysis yielded
remarkably similar and statistically highly significant
findings, suggesting homogeneity of biochemical proc-
esses in ccRCC, as well as the veracity of our data, using a
relatively small sample number.
Proteins from these tissues were extracted and purified
using buffers optimized for maximum protein recovery
from renal tissue, and separated by high-resolution 2-
dimensional gel electrophoresis as described in Methods.
Proteins identified as significantly overexpressed and
underexpressed in tumors as compared to their corre-
sponding control tissues (Delta 2D analysis, see Materials
and Methods) were extracted from gels, in-gel digested
with trypsin, and prepared for mass spectrometric (MS)
analysis. Proteins were identified by peptide mass finger-
printing (Mascot), MS/MS de novo sequencing and
BLASTP2 sequence matching[7].
When examined for up- or down-regulation in ccRCC as
compared to adjacent control renal tissue, we identified
46 spots by MS with a high degree of confidence (Fig. 1;
average Mascot score of 459 and average sequence cover-
age of 47%; see Supplemental Table 1 for a list of all the
identified proteins). Of the 46 identified proteins (Sup-
plemental Table 1), 31 showed significant changes with p
value < 0.05 (Table 1). Quantification of up-regulated
proteins in tumor tissue showed increases from 2-fold to
over 30-fold when compared to expression in normal
control renal tissue. Examples of MS and MS/MS spectra
for one of the proteins identified, Hsp27 (official NCBI
symbol HSBP1), are shown in Fig. 2 and an annotation of
de novo amino acid sequence is shown in Supplemental
Fig. 1. This protein is also labeled in Fig. 1 as HSBP1.
Confirmation of proteomic analysis: identification of 
Hsp27 and PKM2
To confirm that the proteomic analysis utilized was
indeed valid, we performed further analysis of two of the
highly upregulated spots that were identified by MS as
Hsp27 and PKM2 (Figs. 3, 4). The Hsp27 protein, which
lies downstream of p38MAPK, is a member of the heat-
shock class of proteins which play pivotal roles in a variety
of cellular processes such as stress and apoptosis. Hsp27 is
of particular interest to our laboratory because it has been
described to have anti-apoptotic functions[8] and lies
downstream of p53 [9], similar to what we and others
have described for p21. [10-12].
Hsp27 abundance was increased when assessed by immu-
noblotting (Fig. 3) and immunohistochemistry (Supple-
mental Fig. 2) of these tumors, confirming the proteomics
data. In addition, two representative RCC tumors and
adjacent normal tissue, and three RCC cell lines (786-0,
ACHN and SN12C) were examined for Hsp27 and phos-
pho-Hsp27. While none of the kidney cancer cell lines
showed phospho-Hsp27, both of the tumors showed a
high degree of phosphorylation of Hsp27 as compared to
the adjacent normal tissue (Fig. 3a). This result is consist-
ent with a lower than predicted isoelectric point of Hsp27
on 2D gels, which already indicated that the up-regulatedPage 2 of 17
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Molecular Cancer 2006, 5:64 http://www.molecular-cancer.com/content/5/1/64Hsp27 is phosphorylated (theoretical pI = 6.0; actual pI
on 2D gels = 5.3). Because the phospho-peptide does not
ionize well, we were not able to observe it directly in the
mass spectra.
We next examined changes in the levels of PKM2 in ccRCC
and control tissues by immunoblotting (Fig. 4). In the
absence of pVHL, as in VHL-deficient RCCs occurring in
VHL disease, HIF-1α is constitutively activated (due to
lack of degradation), such that these tumors behave as
though they are constitutively hypoxic even though they
are in fact flush with oxygen[1]. PKM2 is of special impor-
tance in RCC, since it is transcriptionally activated by HIF-
1. Furthermore, hypoxic treatment of various cancer cell
lines result in increased PKM2 mRNA[13], suggesting that
this protein may be important in the HIF-1 response, as is
most pronounced in VHL-deficient RCCs. Confirming our
proteomic analysis, we found that PKM2 is markedly
increased in the tumor tissues examined (Fig. 4).
Many of the other proteins we have identified by 2-
dimensional gel analysis as altered in ccRCC have been
confirmed in other published studies in RCC as well as
other cancers, attesting to the validity of our analyses; for
Proteomic analysis of RCCFigure 1
Proteomic analysis of RCC. 2-D gel electrophoresis shows proteins decreased (blue) or increased (red) in ccRCC as compared 
to adjacent normal renal tissue. Numbers 101 – 110 refer to the 10 internal standard spots used for normalization (see Mate-
rials and Methods)Page 3 of 17
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protein changes by single protein immunoblotting.
Network, pathway, and process analyses of significantly 
changed proteins in RCC
The 31 proteins which we identified by mass spectrometry
with p value < 0.05 are listed in Table 2 with their associ-
ated molecular function and biological process(es). Most
of these proteins have previously been described as
involved in one or several cancer types (Table 2). They
also have known interactions amongst themselves and
most form a biological network as illustrated by the soft-
ware Pathway Architect (Stratagene) (Fig. 5). Interestingly,
network analysis pointed to the involvement of TNFα in
ccRCC pathogenesis. Such association has been previ-
ously reported[14,15], and in this manner, our network
analysis can reveal signaling molecules that are likely to be
involved in the disease process but which are not identi-
fied in our analytical assays. This analysis, in particular,
suggests further examination of the use of clinically avail-
able TNFα inhibitors (such as thalidomide and etaner-
cept) for treatment of ccRCC.
We next used statistical tools to analyze the biological
processes and molecular functions as well as the pathways
which encompass the 31 significantly differential proteins
in Table 1. Using the Panther HMM algorithm based on
homology and trained on known proteins, we identified
key processes associated with our 31 protein series (Table
3). After adjusting the p-value with Bonferroni correction
for multiple testing, we found that glycolysis (4 E-05), car-
bohydrate metabolism (3 E-04) and amino acid metabo-
lism (5 E-04) are the only processes with significant p-
values (< 1 E-02) among the 242 Panther biological proc-
esses (Fig. 6 and Supplemental Fig. 3). Similar analysis
indicates lyase as the only prevalent Panther molecular
function (2 E-03), with the proteins aldolase ALDOB,
lyase ENO2, decarboxylase PCK2 and hydratase ECHS1.
A different approach using statistical tools on the Jubilant
Pathart database yielded similar results (Table 4), with the
most significant pathways also including carbohydrate
and amino acid metabolism. As in the Panther analysis,
glycolysis is again the most significant with p value < 1 E-
05. The Jubilant database contains a greater number of
Table 1: Proteins from our proteomic analysis which were significantly different in ccRCC as compared to normal kidney tissue.
Symbol Protein Name SwissProt ID Entrez Gene ID Ratio RCC: normal kidney Minimum Paired t-test
SUCLG1 succinate-CoA ligase, GDP-forming, alpha subunit P53597 8802 0.2 0.0000
HSPCB heat shock 90kDa protein 1, beta P08238 3326 0.4 0.0001
ALDOB aldolase B, fructose-bisphosphate P05062 229 0.1 0.0001
PRDX1 peroxiredoxin 1 Q06830 5052 0.3 0.0002
ECHS1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial P30084 1892 0.3 0.0002
GATM glycine amidinotransferase (L-arginine:glycine 
amidinotransferase)
P50440 2628 0.3 0.0003
ASS argininosuccinate synthetase P00966 445 0.3 0.0008
ATP5H ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit d
O75947 10476 0.4 0.0010
HSPD1 heat shock 60kDa protein 1 (chaperonin) P10809 3329 0.4 0.0019
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, 
delta subunit
P30049 513 0.3 0.0029
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) Q16822 5106 0.3 0.0033
CALB1 calbindin 1, 28kDa P05937 793 0.3 0.0035
BHMT betaine-homocysteine methyltransferase Q93088 635 0.5 0.0041
ACY1 aminoacylase 1 Q03154 95 0.4 0.0043
AKR1A1 aldo-keto reductase family 1, member A1 (aldehyde 
reductase 2ALR)
P14550 10327 0.4 0.0054
AGMAT agmatine ureohydrolase (agmatinase) Q9BSE5 79814 0.5 0.0064
ACAT1 acetyl-Coenzyme A acetyltransferase 1 (acetoacetyl 
Coenzyme A thiolase)
P24752 38 0.4 0.0078
GSTO2 glutathione-S-transferase, alpha-class, omega 2 subunit P08263 119391 0.4 0.0101
PKM2 pyruvate kinase, muscle P14618 5315 14.7 0.0170
ANXA4 annexin A4 Q6P452 307 2.7 0.0225
ANXA5 Annexin V P08758 308 2.3 0.0245
HSPB1 heat shock 27kDa protein 1 P04792 3315 2.4 0.0256
FABP7 fatty acid binding protein 7, brain O15540 2173 6.3 0.0262
TBB2 tubulin, beta polypeptide P07437 7280 19.5 0.0264
ENO2 enolase 2, (gamma, neuronal) P09104 2026 32.8 0.0364
LDHA lactate dehydrogenase A P00338 3939 3.8 0.0383
CLIC1 chloride intracellular channel 1 O00299 1192 2.8 0.0414
GAPDH glyceraldehyde-3-phosphate dehydrogenase P04406 2597 2.1 0.0450
PSME2 proteasome (prosome, macropain) activator subunit 2 
(PA28 beta)
Q9UL46 5721 2.2 0.0460
CSTB cystatin B (stefin B) P04080 1476 4.0 0.0464
HINT1 histidine triad nucleotide binding protein 1 (PKCi substrate 
analog)
P49773 3094 2.4 0.0482Page 4 of 17
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Molecular Cancer 2006, 5:64 http://www.molecular-cancer.com/content/5/1/64metabolic processes than the Panther database, and sev-
eral other carbohydrate metabolic pathways, such as pro-
panoate, pyruvate, butanoate metabolism, urea cycle and
citrate cycle, are identified with a significant p value < 5 E-
Anti-apoptotic proteins are upregulated in ccRCC as confirmed by immunoblottingFigure 3
Anti-apoptotic proteins are upregulated in ccRCC as confirmed by immunoblotting. Three RCC cell lines, and 2 tumors which 
were used in the proteomic analysis were immunoblotted with Hsp27 or phospho-Hsp27 antibodies; actin is a loading control. 
Solid line indicates same kidney.
MS and MS/MS spectra for HSP27Figure 2
MS and MS/MS spectra for HSP27. A) MS spectrum of HSP27. The peptide whose MS/MS spectrum is shown in panel B is indi-
cated. B) MS/MS spectrum of the peptide ion m/z 1163 obtained in CID mode.
A) B)Page 5 of 17
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degradation, valine, leucine and isoleucine degradation
are also identified. The only significant non-metabolic
pathway is the p53-mediated pathway with 6 proteins
among the 31 proteins, yielding a p value < 4 E-04 (vide
infra). The six proteins, lactate dehydrogenase (LDHA),
glyceraldehyde 3-P dehydrogenase (GAPDH), Hsp27
(HSPB1), proteasome activator subunit 2 (PSME2), pyru-
vate kinase (PKM2) and the annexins A4 and A5 (ANXA4
and ANXA5) have all been associated to at least one type
of cancer (breast, colon, kidney, liver, lung, ovarian, pan-
creatic); this association is further confirmatory regarding
the veracity of our data and analyses.
We next sought to integrate our data into a known extant
pathway scheme, and for this analysis we chose the most
significantly enriched pathway which we identified in this
study. As shown in the KEGG glycolysis and gluconeogen-
esis diagram (Fig. 7), those glycolysis enzymes which we
identified among the 31 altered proteins are all upregu-
lated, including ALDOA (aldolase A) with p value = 0.051
(Supplemental Table 1) but excluding ALDOB (aldolase
B), a fructose-bisphosphate which we found was down-
regulated with p value < 0.01. Lactate dehydrogenase,
which activity in general is linked to hypoxia, is upregu-
lated. In contrast, several carbohydrate metabolic path-
ways closely associated with glycolysis, such as
pentanoate metabolism, pyruvate metabolism, and citrate
cycle, are all down regulated. This is true also for the other
significantly enriched pathways, arginine and proline
metabolism and the urea cycle, both with enzymes (ASS,
GATM, AGMAT and ACY1) being down regulated (Fig. 7).
The only significantly enriched non-metabolic pathway is
the p53 mediated pathways (p value = 4 E-05) with 6 pro-
teins among our 31 identified proteins (HSPB1, PKM2,
PSME2, ANXA4, ANXA5, GAPDH and LDHA). This is not
unexpected given the pivotal role played by the tumor
suppressor proteins in DNA damage repair and, conse-
quently, response to chemotherapy (reviewed in [10]).
Elements of the pathway have been targeted by our labo-
ratory and others as possible chemotherapy sensitizers in
other cancers[10,12], and may be relevant to RCC as well.
Thus this finding is not only confirmatory about the verac-
ity of our data, but supports the continued investigation
of mTOR inhibitors for ccRCC; these drugs act through
attenuation of an element of the p53 pathway, p21[16],
The HIF-1 target, PKM2, is increased in ccRCC as confirmed by immunoblottingFigure 4
The HIF-1 target, PKM2, is increased in ccRCC as confirmed by immunoblotting. Two tumors which were used in the pro-
teomic analysis were immunoblotted with PKM2 antibody; actin is a loading control. Solid line indicates same kidney.Page 6 of 17
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Table 2: Annotation of proteins which were significantly altered in ccRCC as compared to norml tissue.
Symbol Gene Entrez Gene ID Biological Process Molecular Function Associated Cancer
ACY1 aminoacylase 1 95 Amino acid biosynthesis Hydrolase;Metalloprotease
ASS argininosuccinate synthetase 445 Amino acid 
biosynthesis;Nitrogen 
metabolism
Ligase liver cancer
AGMAT agmatine ureohydrolase (agmatinase) 79814 Amino acid catabolism Hydrolase
BHMT betaine-homocysteine 
methyltransferase
635 Amino acid metabolism Methyltransferase
GATM glycine amidinotransferase (L-
arginine:glycine amidinotransferase)
2628 Amino acid metabolism Transferase
CLIC1 chloride intracellular channel 1 1192 Anion transport;Other 
homeostasis activities
Anion channel breast and ovarian cancers
PRDX1 peroxiredoxin 1 5052 Antioxidation and free radical 
removal
Peroxidase breast, liver and 
pancreatic cancers
GSTO2 glutathione-S-transferase, alpha-class, 
omega 2 subunit
119391 Detoxification;Antioxidation and 
free radical removal
Transferase ovarian cancer
ECHS1 enoyl Coenzyme A hydratase, short 
chain, 1, mitochondrial
1892 Carbohydrate metabolism;Fatty 
acid beta-oxidation;Coenzyme 
metabolism;Vitamin biosynthesis
Synthetase;Dehydrogenase;Ace
tyltransferase;Acyltransferase;H
ydratase;Epimerase/
racemase;Ligase
liver cancer
PCK2 phosphoenolpyruvate carboxykinase 2 
(mitochondrial)
5106 Gluconeogenesis Decarboxylase liver cancer
AKR1A1 aldo-keto reductase family 1, member 
A1 (aldehyde reductase 2ALR)
10327 Glucose metabolism; aldehyde 
metabolism
Reductase breast cancer
ALDOB aldolase B, fructose-bisphosphate 229 Glycolysis Aldolase liver cancer
ENO2 enolase 2, (gamma, neuronal) 2026 Glycolysis Lyase breast, lung and prostate 
cancers
GAPDH glyceraldehyde-3-phosphate 
dehydrogenase
2597 Glycolysis Oxidoreductase liver, lung and ovarian 
cancers
LDHA lactate dehydrogenase A 3939 Glycolysis Dehydrogenase breast and ovarian cancers
PKM2 pyruvate kinase, muscle 5315 Glycolysis Carbohydrate kinase ovarian cancer
SUCLG1 succinate-CoA ligase, GDP-forming, 
alpha subunit
8802 Tricarboxylic acid pathway Synthetase breast cancer
FABP7 fatty acid binding protein 7, brain 2173 Lipid and fatty acid 
transport;Lipid and fatty acid 
binding; Vitamin/cofactor 
transport;Steroid hormone-
mediated 
signaling;Transport;Ectoderm 
development
Transfer/carrier protein breast cancer
ANXA4 annexin A4 307 Lipid, fatty acid and steroid 
metabolism
Transfer/carrier 
protein;Annexin
pancreatic cancer
ANXA5 Annexin V 308 Lipid, fatty acid and steroid 
metabolism
Transfer/carrier 
protein;Annexin
breast and pancreatic 
cancers
ACAT1 acetyl-Coenzyme A acetyltransferase 1 
(acetoacetyl Coenzyme A thiolase)
38 Protein acetylation Acetyltransferase liver cancer
HSPD1 heat shock 60kDa protein 1 
(chaperonin)
3329 Protein folding;Protein complex 
assembly
Chaperonin lung cancer
HSPB1 heat shock 27kDa protein 1 3315 Protein folding;Stress response Chaperones Colon, breast, ovarian 
cancer and pancreatic 
cancers
HSPCB heat shock 90kDa protein 1, beta 3326 Protein folding;Stress response Hsp 90 family chaperone
CSTB cystatin B (stefin B) 1476 Proteolysis Cysteine protease inhibitor prostate cancer
PSME2 proteasome (prosome, macropain) 
activator subunit 2 (PA28 beta)
5721 Proteolysis Miscellaneous function protein breast cancer
CALB1 calbindin 1, 28kDa 793 Calcium mediated 
signaling;Calcium ion 
homeostasis
Select calcium binding protein
TBB2 tubulin, beta polypeptide 7280 Intracellular protein 
traffic;Chromosome 
segregation;Cell structure;Cell 
motility
Protein polymerization breast cancer
ATP5D ATP synthase, H+ transporting, 
mitochondrial F1 complex, delta subunit
513 Nucleoside, nucleotide and 
nucleic acid metabolism;Electron 
transport;Cation transport
Hydrogen 
transporter;Synthase;Other 
hydrolase
lung cancer
ATP5H ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit d
10476 ATP synthesis coupled proton 
transport
ATP synthase lung and ovarian cancer
HINT1 histidine triad nucleotide binding 
protein 1 (PKCi substrate analog)
3094 Signal transduction Nucleotide phosphatase breast cancer
Molecular Cancer 2006, 5:64 http://www.molecular-cancer.com/content/5/1/64which is anti-apoptotic[11], pro-proliferative[17], and
has prognostic value in ccRCC[5].
Transcriptomic validation of proteomics results
There are several existing published studies on transcrip-
tomic analysis of RCC; while not repeating such genomic
studies, we used the microarray data generated by Taka-
hashi et al[18] to confirm our results. We re-annotated the
genes, which these investigators had determined to be sig-
nificantly differential when comparing mRNA expression
from RCC and normal renal tissue, using the most
updated annotation database available. From these
results, we generated a list of 88 genes with the NCBI Ent-
rez identifier and used this list for pathway analysis with
the Jubilant PathArt database. While only seven genes
from this list correspond to the proteins identified in our
study (ENO2, ALDOB, CALB1, ASS, ACY1, SUCLG1,
GATM), the process analysis yielded remarkably similar
results to our proteomic results (Table 5), with carbohy-
drate metabolism and amino acid metabolism being the
most significant pathways, in particular glycolysis, and
arginine and proline metabolism (p = 1 E-05). Urea cycle
and citrate cycle were also significant in this analysis, as
well as those for sterol, vitamin K, vitamin E and caroten-
Network of interactions between the 31 differentially expressed proteinsFigure 5
Network of interactions between the 31 differentially expressed proteins. TNF is not one of the 31 proteins but is shown here 
as it interacts with many components of the network. Nodes represent proteins and links indicate known interactions or mod-
ulations from neighboring nodes. Proteins at the bottom of the figure are in the 31 protein set but are not involved in the net-
work. Links scheme -gray square: regulation; -green square: direct regulation; -green circle: promoter binding; -green open 
square: molecular transport; -blue open square: molecular synthesis; -blue square: expression; -yellow circle: protein modifica-
tion; -purple circle: binding.
Table 3: Enriched processes identified with the Panther libraries using proteins which were significantly altered in ccRCC as compared 
to normal tissue, with p < 0.05. The pvalue is then adjusted with Bonferroni correction for multiple testing.
Biological Process (Panther) RCC Proteins H. sapiens Ref. pValue
Glycolysis 4 41 4.20E-05
Carbohydrate metabolism 7 584 2.90E-04
Amino acid metabolism 5 238 4.60E-04Page 8 of 17
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with our proteomic data is further validation of its verac-
ity.
Urinary metabolic profiling verifies an identified altered 
pathway
Because some of the processes identified above may result
in metabolic ''signatures'' in the urine which would be
useful for RCC diagnosis as well as therapeutic responsive-
ness, we next performed a pilot study by metabolic profil-
ing of several urines from RCC patients in an attempt to
identify metabolites which are expected to result from
activation of the enzymes involved in the above processes.
We focused on intermediate or end-products of the glyco-
lysis pathways, since this is expected based on the process
analysis described above.
We identified 40 primary metabolites in the urine of 5
ccRCC and 5 control patients (distinct from those patients
from whom the kidney tissue was obtained). While no
phosphorylated intermediates were present in urine, we
were able to identify a variety of small molecule glycolytic
intermediates, such as glucose, pyruvate, sorbitol, and
succinate, and TCA cycle intermediates such as malate and
aconitate but not oxaloacetic acid, fumarate, citrate and
isocitrate. From these 40 metabolites, only the sorbitol
level was significantly altered at p = 0.02 with a 5.4-fold
higher level in the ccRCC patients as compared to control
samples (Table 6).
The use of creatinine as reference for urinary excretion vol-
umes and metabolism is frequently questioned due to the
biological variability of creatinine itself. When raw data
are normalized to the sum of all detected metabolites
instead solely to creatinine, mannitol and myo-inositol
also become significantly increased in RCC patients (p <
0.05). Both compounds refer to sugar alcohol metabolism
and indicate that a combined assay on reduced sugars may
serve as stronger and more valid diagnostic biomarker
than just a single compound alone. This finding is in
accordance to the general anoxic state of cancer cells that
favors reductive metabolism and thus may be indicated by
reducing glucose directly to sugar alcohols in side reac-
tions.
Discussion
While a relatively infrequent malignancy, kidney cancer is
distinguished by its being associated with notably unsat-
isfactory treatment options. Thus, the identification of
biomarkers in easily accessible patient materials (such as
blood and urine) is needed in order to identify affected
patients while the disease is not metastatic and the tumor
is still resectable. In this study, we have utilized several
''omic'' techniques to identify candidate pathways and
networks which are altered in ccRCC and which can there-
fore be utilized in designing a diagnostic test for patients
at higher risk for this disease, as well as to suggest novel
therapeutic approaches. In light of the fact that reproduc-
ibility and variability of obtained data dictate optimal
sample size in proteomics studies, our highly concordant
results (validated by immunoblotting, high confidence p-
values, and corroboration of our data with independently
published proteomic and transcriptomic data) underscore
the accuracy of our data, despite its relatively small sample
size.
In order to confirm our proteomic analysis, we examined
two separate proteins which were found to be significantly
altered by 2D gel electrophoresis and MS identification.
These two proteins were selected because they play key
roles in oncogenesis and/or response to therapy as
detailed below. Levels of Hsp27 have been reported to be
elevated in kidney[19], breast[20], and liver[21] cancers,
as has the phosphorylated form[22]. Using proteomic and
then immunoblotting analysis in RCC, we have con-
firmed that phospho (but not native) Hsp27 is elevated in
Table 4: Enriched processes and pathways identified with the Jubilant PathArt database using proteins which were significantly altered 
in ccRCC as compared to normal tissue, with p< 0.05.
Process or Pathway (Jubilant PathArt) RCC Proteins H. sapiens Ref. pValue
Glycolysis/Gluconeogenesis 7 34 < 1.00E-05
Propanoate Metabolism 5 33 1.00E-05
Pyruvate Metabolism 5 37 1.00E-05
Arginine And Proline Metabolism 4 62 2.00E-05
Urea Cycle 4 38 2.00E-05
p53 Mediated Pathway 6 154 3.20E-04
Butanoate Metabolism 3 41 0.00196
Citrate Cycle 3 43 0.00224
Sterol, Vitamin K, Vitamin E, Carotenoids Biosynthesis 3 46 0.00271
Lysine Degradation 3 54 0.00422
Valine, Leucine And Isoleucine Degradation 3 56 0.00466
Purine Metabolism 4 121 0.00582
FAS Signaling Pathway 3 136 0.04344Page 9 of 17
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Molecular Cancer 2006, 5:64 http://www.molecular-cancer.com/content/5/1/64ccRCC in a parallel manner to p21. These findings were of
special interest, since both proteins are induced by p53
[9], and there are reports that elevated levels of
Hsp27[20], as p21[5], are associated with decreased
patient survival. These data are also consistent with our
pathway analysis showing that the p53 pathway is altered
in ccRCC (Table 4).
Our proteomic analysis is not exhaustive, and is biased
toward identification of high abundance soluble proteins
as is normal for 2D gel-based approaches. Proteins with
molecular masses higher than 150 kDa and lower than 15
kDa as well as proteins with isoelectric points outside the
range of pH 3 – 10 are not identified. In addition, hydro-
phobic membrane proteins are underrepresented on 2D
gels. Nevertheless, most cellular proteins have properties
that make them amendable to the 2D gel approach, and
liquid chromatography-based approaches (1D and 2D)
have other pitfalls.Furthermore, high-abundance proteins
which are altered in RCC are those which are most likely
to have an impact on RCC-specific alteration of cellular
phenotype. Finally, we performed comprehensive path-
way analysis which allows us to identify the enriched bio-
logical networks, pathways, and processes involved, using
only fractional information generated with the 2D gels,
thereby alleviating at least some of the limitations of this
technology.
Our pathway analysis has allowed us to identify groups of
genes and proteins which are organized into metabolic
and signaling pathways relevant to the oncogenesis or
progression of ccRCC. The two different and independent
Significant Panther Biological Process (p < 0.01) shown in yellowFigure 6
Significant Panther Biological Process (p < 0.01) shown in yellow. The RCC 31 protein set is compared to a human reference 
set of 23,401 translated transcripts and allocated in 242 biological process classes. Two sections of the histogram, encompass-
ing glycolysis and amino acid metabolism pathways, are shown here; the complete histogram is available in Supplemental Fig. 3. 
Red bars correspond to percentage of proteins attributed to a given process, when looking at the 23,401 human reference set. 
Blue bars indicate the percentage of proteins from the RCC 31 protein sets in that class. Yellow bars indicate the process 
which we identified from our proteomic analysis to have a significance greater than 0.01. Glycolysis is the most significant path-
way identified by this analysis.Page 10 of 17
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Proteins differentially regulated in RCC involved in carbohydrate metabolism are shown overlaid on the glycolysis and glucone-ogenesi pathway KEGG #00010 diagram. Anaerobic glycolysis is upregu ated while other carbohydrat s metabolism appears down regulatedFigure 7
Proteins differentially regulated in RCC involved in carbohydrate metabolism are shown overlaid on the glycolysis and glucone-
ogenesis pathway KEGG #00010 diagram. Anaerobic glycolysis is upregulated while other carbohydrates metabolism appears 
down regulated. The enzymes colored in red correspond to the proteins which we found upregulated in ccRCC, and in green 
those (or pathways associated) we found downregulated in ccRCC. We added the corresponding gene symbol next to the 
enzyme or enriched process.
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result in similar findings: glycolysis enzyme levels are the
most significantly altered in ccRCC. This is in agreement
with other studies in various cancers[23,24]. Also in agree-
ment with these published results[23], we observed simi-
lar patterns of expression for the proteins aldolase-
fructose-bisphosphate ALDOB and ALDOA, with the
former being upregulated and the latter downregulated.
Furthermore, while we have not performed a de novo tran-
scriptomic study on the same samples used for this pro-
teomics analysis, we have examined and updated the
microarray data on ccRCC obtained by Takahashi et al[18]
and found that these data are consistent with our pro-
teomic results. All of these concordant results underscore
the pertinence of our data, despite the fact that it has been
generated from a relatively small sample set.
In this study, we show with a high degree of statistical con-
fidence that other pathways closely associated with gluco-
neogenesis, such as pyruvate metabolism, pentanoate
metabolism, butanoate metabolism, as well as arginine
and proline metabolism and the urea cycle, are downreg-
ulated in ccRCC. In contrast, as for pyruvate being a sub-
strate, we observed an increase in lactate dehydrogenase
(LDHA), which is known to be playing an active role in
anaerobic glycolysis, thus reflecting the hypoxic condi-
tions known to be present in proliferating cancer cells,
especially RCC. LDHA increase has been shown in a vari-
ety of cancers but the hypothesis that LDHA is involved in
an apoptotic pathway[25] could imply a more complex
role of this enzyme in ccRCC.
We have correlated our transcriptomic and proteomic
results with an analysis of metabolites in the urine and
found compounds which could result from activation of
the carbohydrate metabolism pathways, in particular the
glycolysis and gluconeogenesis pathways; such urine
metabolites could conceivably be utilized as part of a
screening procedure for RCC, as we describe. Metabo-
lomic analysis in principle has considerable promise for
translation of basic science data to the clinic in a variety of
diseases[26]. Nephrologic disorders are particularly ame-
nable to metabolomic analysis, since the urine is the final
repository for a number of metabolites. However, since
metabolomic analysis is quite dependent on a number of
variables such as diet and medications, detection of the
pathways involved in this pathology, and which theoreti-
cally result in identifiable metabolites, increases the
chance of success in this type of analysis. Our finding that,
of the 40 metabolites profiled in the urine, sorbitol was
significantly elevated in the ccRCC patients' urine suggests
that the sorbitol pathway of glucose metabolism is active
in the RCC kidneys. While sorbitol acts as an intracellular
osmolyte to protect medullary cells from the hypertonic
extracellular milieu (see below)[27], activation of the
sorbitol pathway is also seen in states of hyperglycemia,
and thus in states in which glycolysis is active[28]. This is
consistent with our finding of elevated glycolysis pathway
enzymes by our proteomic (and historical genomic) anal-
ysis; however, this data awaits confirmation in a larger
sample size.
Sorbitol is one of the small organic solutes (osmolytes)
that are accumulated within the cells of the renal medulla
and protects these cells against high medullary tonicity.
Thus, it is possible that sorbitol is altered due to a change
in osmolality of the urine[27]. However we measured
urine osmolality in RCC and control urines (data not
Table 5: Enriched pathways identified with Jubilant PathArt database, using genes identified in ccRCC microarray experiment 
published by Takahashi et al [18].
Pathways (Jubilant PathArt) RCC Genes H. sapiens Ref. pValue
Glycolysis/Gluconeogenesis 8 49 < 1.00E-05
Arginine And Proline Metabolism 7 92 1.00E-05
Urea Cycle 5 48 2.00E-05
Phenylalanine Metabolism 3 18 1.80E-04
Lysine Degradation 4 54 3.20E-04
Valine, Leucine And Isoleucine Degradation 4 56 3.70E-04
Nicotinate And Nicotinamide Metabolism 3 32 9.70E-04
Propanoate Metabolism 3 33 0.00106
Starch And Sucrose Metabolism 3 40 0.00183
Citrate Cycle 3 43 0.00224
Sterol, Vitamin K, Vitamin E, Carotenoids Biosynthesis 3 46 0.00271
Terpenoid Biosynthesis 2 13 0.00280
Phenylalanine, Tyrosine And Tryptophan Biosynthesis 2 17 0.00476
Purine Metabolism 4 121 0.00582
Cysteine Metabolism 2 21 0.00718
Pantothenate And CoA Biosynthesis 2 21 0.00718
Tyrosine Metabolism 3 67 0.00754Page 12 of 17
(page number not for citation purposes)
Molecular Cancer 2006, 5:64 http://www.molecular-cancer.com/content/5/1/64shown) and did not find a significant difference, arguing
against (but not disproving) this mechanism. Sorbitol
may be increased as a result of non-specific derangement
of kidney cell osmolar function. However, it is also possi-
ble that sorbitol is being produced by alternate glycolysis
pathways in the tumors and that our observation of
decreased aldehyde reductase activity in the RCCs reflects
feedback inhibition of expression of this enzyme. Such
enzymes are part of the aldo-keto reductase super family
and represent monomeric NADPH-dependant oxidore-
ductases that have a wide substrate specificity for carbonyl
compounds[29]. This is of some interest, as it has been
shown that sorbitol causes resistance to some chemother-
apeutic agents[30], such that its production by the RCC
tumors that we examined in this study may be a mecha-
nism of chemoresistance. Whether there are other patho-
physiological functions for sorbitol or its pathway
enzymes in RCC is unknown but currently under active
investigation in our laboratory.
It has indeed been known since the 1920's that advanced
tumors have high rates of glycolysis[31], however, trans-
lating this finding into a diagnostic assay has not, to our
knowledge, been attempted. Using two independent
approaches, we demonstrate in this study that glycolysis
related enzymes played a major role in the metabolism of
Table 6: Primary metabolites differentially expressed in urine of ccRCC and normal control patients (creatinine not shown).
Compound pValue Mean Fold Change
Sorbitol 0.02 5.4
Glycerol 0.08 3.7
Palmitate 0.08 2.8
myo-Inositol 0.1 11.5
Pelargonic acid 0.1 2.4
Gluconic acid 0.16 1.9
Fructose 0.16 1.7
Stearic acid 0.18 1.7
Hippuric acid 0.22 0.5
Mannitol 0.24 1.4
N-Acetylglucosamine 0.26 1.6
Malic acid 0.3 5.7
Ethanolamine 0.32 0.7
Galactose 0.33 1.6
Threonic acid 0.34 1.5
Sucrose 0.35 0.7
1,6-anhydro-beta-glucopyranose 0.36 0.6
m-Cresol 0.37 0.6
Quinic acid 0.37 0.6
Ribose 0.39 1.5
Capric acid 0.47 2.1
Erythronic acid 0.51 1.6
Xylose 0.54 1.3
Glucose 0.54 0.8
5-ε-Hydroxybutylhydantoin 0.55 1.4
Xylitol 0.56 1.5
Threitol 0.59 1.2
Ribitol 0.6 1.3
Tetronate 0.63 1.2
4-Hydroxybenzoate 0.66 0.7
Succinate 0.69 0.7
4-Hydroxyphenylacetic acid 0.78 0.8
Oxoproline 0.82 0.9
Pyruvate 0.83 0.8
Gluconic acid 0.85 1.1
Rhamnose 0.86 0.9
Aconitic acid 0.87 0.9
Lactate 0.87 0.9
Erythritol 0.95 1Page 13 of 17
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bolic "signature" in the urine of activation of this pathway
is the first such report. It is possible, of course, that this
urinary signature is not unique to RCC but may be the
result of the presence of any malignancy, given the known
high glycolysis rates[31,32]. In addition, this may be an
effect intrinsic to the kidney, although this is unlikely
given the significant difference between malignant and
control tissue. These studies are currently underway in our
laboratories.
In this study, we utilized proteomic analysis of tumors to
determine which pathways and processes are likely to be
operative in kidney cancer, and, supporting our findings,
extant genomic analysis from other laboratories is consist-
ent with our data identifying the glycolysis pathway as
being significantly altered in ccRCC. We utilized these
identified pathways to discover a metabolic signature in
the urine of ccRCC patients as products of glycolysis and
sugar alcohol metabolism. Thus, in this study, we have
taken a systems approach to RCC, utilizing proteomics to
identify pathways altered in this disease, confirming our
results with existing transcriptomic data, and then success-
fully identifying a metabolic signature in the urine of RCC
patients. While levels of single small metabolites may lack
diagnostic specificity, subsequent studies of more patients
and additional metabolites may lead to patterns of metab-
olites whose appearance will lead to novel urinary diag-
nostic tests for ccRCC in high risk patients. In addition,
alterations to these pathways (especially the p53 and FAS
signaling pathways, see Table 4) will allow clinicians to
better tailor therapies (such as DNA-damaging chemo-
therapies and mTOR inhibition as discussed above) to
specific patients, as well as to monitor the molecular
effects of therapy prior to gross tumor changes.
Conclusion
In this study, we have used proteomic and metabolomic
techniques to study tissue and urine, respectively, by net-
work, pathway and process analysis in clear cell renal cell
carcinoma patients to demonstrate those biochemical
processes which are activated in the disease. Knowledge of
these pathways will ultimately lead to novel assays for
their metabolic signatures in patient biofluids, and we
have begun to examine urine metabolomics to confirm
this likelihood. Such assays will ultimately be useful for
early diagnosis of disease in high risk patients as well as
choice of, and response to, specific therapies.
Methods
Materials
Goat polyclonal Hsp-27 and rabbit polyclonal phospho-
Hsp27 antibodies were obtained from Santa Cruz Bio-
technology and used at a 1:1000 and 1:200 dilutions,
respectively. Goat polyclonal PKM-2 antibody was
obtained from Novus and used at a dilution of 1:1000.
Horseradish peroxidase-conjugated anti-rabbit IgG and
horseradish peroxidase-conjugated anti-mouse IgG was
obtained from Bio-Rad and used at a 1:15000 dilution.
Reagents for the Enhanced Chemiluminescence system
were obtained from Amersham Pharmacia. All other rea-
gents were from Sigma. RCC and adjacent control tissue
was obtained from the UC Davis tissue bank after appro-
priate Institutional Review Board approvals (UCD
IRB#200312072-3), and the urine samples from cancer
patients were obtained from the Cooperative Human Tis-
sue Network (CHTN) at Vanderbilt University.
Western blots
The RCC cell lines 786-0, ACHN were obtained from
ATCC, and SN12C as a kind gift from Dr. Isaiah J. Fidler.
Equal protein quantities were electrophoresed and West-
ern-blotted as described[33]. To confirm equal protein
loading blots were either reprobed with β-actin or equal
amounts of lysates were loaded in duplicate lanes in the
same gel and separated after transfer to be probed for β-
actin separately.
Immunohistochemistry
Formalin fixed, paraffin embedded tissue blocks of the
human kidney tumor samples were sectioned at 4-5
micron thickness, mounted on charged glass slides and
baked for one hour at 60°C. Slides were deparaffinized
with 3 changes of xylene, and the endogenous peroxidases
were quenched with hydrogen peroxide, followed by a
series of ethanol rinses (100%, 100%, 95%, and 70%).
Slides were rehydrated and prepared for antigen retrieval
with citrate buffer and blocked with 10% goat serum
diluted in PBS. After incubation with phospho-Hsp27
antibody (1:50) in PBS + 0.05% BSA overnight, slides
were rinsed in PBS and incubated with anti-goat second-
ary antibody (Jackson ImmunoResearch 1:1000), and
incubated with DAB (Vector) following vender instruc-
tions. Slides were counterstained in Mayer's hematoxylin,
dehydrated, cleared, and coverslipped. Slides were photo-
graphed with a Zeiss Axioskop light microscope and Axio-
cam digital camera
Two-dimensional gel electrophoresis and spot analysis
Proteins were extracted from frozen tissue as previously
described[34]. A total protein concentration of 600 μg in
IPG Rehydration Buffer containing 15 mM DTE and 0.5%
ampholytes pH 3–10 (Amersham Biosciences) was
loaded on 17-cm IPG strips pH 3–10 non-linear (NL)
from Bio-Rad (Hercules, CA) using passive rehydration at
20°C. Isoelectric focusing was performed using the Pro-
tean IEF cell (Bio-Rad) for 65,000 Vh. After equilibration
IPG strips were loaded on uniform 11% polyacrylamide/
bis-acrylamide gels (Protean Xi, Bio-Rad) and electro-
phoresed at 20 mA constant current at 10°C. Gels werePage 14 of 17
(page number not for citation purposes)
Molecular Cancer 2006, 5:64 http://www.molecular-cancer.com/content/5/1/64stained with Colloidal Coomassie blue and scanned with
an Epson 1680 Scanner as described previously[7]. Spot
quantification and statistical analysis of differences in
spot values were done as previously described[34]. The
protein spots were matched between gels using the All-to-
One warping strategy using the Delta 2D gel analysis soft-
ware from Decodon GmbH (Greifswald, Germany). One
RCC sample gel was selected as the reference gel and all
replicates of all conditions were matched to this gel using
the exact warping method between each gel pair with
defined vectors from sample to Master gel. In order to
ensure that the same spot area was quantified in all gels, a
master gel was created by fusing all gel images with the
maximum intensity option selected in Delta2D. Subse-
quently, the spots in the master gel were detected, using
optimized spot detection parameters with exact spot out-
lines. In some cases spot outlines were manually edited to
separate spots or to eliminate background interference.
The detected spots from the Master gel were then trans-
ferred to all other gels, instead of individually quantifying
each gel, which yielded different spot outlines. To further
ensure uniformity between replicates and to minimize
gel-to-gel variation due to experimental conditions, the
volume of each detected spot was normalized to the sum
total of the volumes of ten internal standard spots (std
110), selected as spots present at visually uniform inten-
sity in all gels and whose total sum ranged between 2 and
4% of the total spot volume in each gel. The standard
deviation of each quadruplicate determination was calcu-
lated based on the absolute spot volumes normalized to
the sum of the internal standards. All further statistical
analyses were performed with Excel using paired RCC and
normal sample spot volume values, normalized to the
sum of internal standards as above. To determine if an
equal or unequal variance existed between variances of
RCC and normal sample spot volumes, an F-test was per-
formed with Alpha:0.05. If the resulting P(F f) was less
than 0.05, unequal variances were assumed; otherwise,
equal variances between conditions were assumed. An
ensuing paired t test with Alpha:0.05 was performed
between spot volume means of RCC and normal samples
on the basis of the results of the F-test. The corresponding
P-value, P(T t), was reported as a measure of significant
statistical variability between conditions.
Up- and down-regulated spots were extracted from gels
and tryptic in-gel digestion and peptide extraction per-
formed as previously described[34]. Each spot was placed
in a single well of a ZipPlate™ (Millipore, Billerica, MA)
containing immobilized C18 resin. Spot processing was
performed at room temperature using reagents provided
in the Montage In-Gel DigestZP Kit (Millipore) as previ-
ously detailed[34].
MALDI-TOF/TOF mass spectrometry
MALDI-TOF/TOF analysis was performed as previously
described[34]. Briefly, MALDI matrix α-cyano-4-hydroxy-
cinnamic acid (HCCA, Sigma, St-Louis, MO) was recrys-
tallized from 70:30 acetonitrile:H2O prior to use and
eluted samples spotted in 0.5 μL-increments on a stainless
steel MALDI plate. They were then overlaid with 2 × 0.5 μL
of 2 mg/mL HCCA. Samples were analyzed on a 4700 Pro-
teomics Analyzer from Applied Biosystems (Foster City,
CA) using both MS and MS/MS operating modes. Peptide
fragmentation in MS/MS mode was achieved either by
post-source decay (PSD) or collision-induced dissociation
(CID) using atmosphere as the collision gas. Protein iden-
tification was carried out with GPS Explorer software
(Applied Biosystems) using the Mascot search algorithm
and DeNovo Explorer modules included in the 4700
Explorer software (Applied Biosystems). The limit for
mass accuracy was set at 50 ppm.
Process and pathway analysis
We used two approaches based on the Panther libraries
[35] and the Jubilant Biosys pathways analysis tool
PathArt. The Panther libraries are based on multiple
sequences alignments and Hidden Markov Models to clas-
sify uncharacterized proteins in protein families, func-
tions and processes. Out of 23401 refseq genes of the
human genome, 56% have been assigned to a Panther
biological process and 57% to a Panther function. The
Jubilant PathArt is a human curated database, containing
pathways and diseases information based on published
data in scientific journals. This dataset is updated quar-
terly and contains to date almost 50,000 interactions from
over 2000 pathways. Both databases, Panther and
PathArt, used simultaneously allows meaningful statisti-
cal evaluation of the process or pathway hits.
For the Panther analysis, the binomial statistics tool is
used to compare classifications of multiple clusters of lists
to a reference list to statistically determine over- or under-
representation of Panther classification categories. Each
list is compared to the reference list using the binomial
test for each molecular function or biological process. The
P-value is then adjusted with the Bonferroni correction for
multiple testing as many statistical tests are performed at
the same time. This correction multiplies the single-test P-
value by the number of independent tests to obtain an
expected error rate.
With Jubilant Biosys PathArt, a two-sided Fisher's exact
test is used to calculate the P-value. A 2X2 contingency
table is used and probabilities are calculated, where the
rows of the table are the user inputs (number of genes in
the pathway and number of genes not in the pathway),
and the columns are data in the database (number ofPage 15 of 17
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pathway).
Metabolic profiling
Due to insufficient enzyme selectivity, no urease treat-
ment was performed prior to metabolite extraction (data
not shown). Metabolite profiling of a select list of 39 iden-
tified compounds was carried out on a gas chromatogra-
phy-time of flight mass spectrometer. 30 μl of urine was
extracted with 0.5 mL of a solution of water/methanol/
chloroform at 2:5:2 at -20°C. For GC-TOF MS (Leco
Pegasus II GC-TOF mass spectrometer; Leco, St. Joseph,
MI, USA) analysis, the organic phase was dried and dis-
solved in 20 μL of methoxamine hydrochloride (20 mg/
mL pyridine) and incubated at 30°C for 90 min with con-
tinuous shaking. Then 180 μL of N-methyl-N-trimethylsi-
lyltrifluoroacetamid (MSTFA) were added to exchange
acidic protons at 37°C for 30 min. The derivatized sam-
ples were stored at room temperature for 120 min before
injection. GC-TOF analysis was performed on an HP 5890
gas chromatograph with tapered, deactivated split/split-
less liners containing glasswool (Agilent, Böblingen, Ger-
many) and 1 μL splitless injection at 230°C injector
temperature. The GC was operated at constant flow of 1
mL/min helium and a 40 m 0.25 mm id 0.25 μm RTX-5
column with 10 m integrated precolumn. The tempera-
ture gradient started at 80°C was held isocratic for 2 min,
and subsequently ramped at 15°C/min to a final temper-
ature of 330°C which was held for 6 min. Twenty spectra
per second were recorded between m/z 85–500. Peak iden-
tification and quantification were performed using the
Pegasus software package (Leco) based on mass spectral
comparison to an in-house library of authentic standards.
Automated assignments of unique fragment ions for each
individual metabolite were taken as default as quantifiers,
and manually corrected where necessary. All artificial
peaks caused by column bleeding or phtalates and polysi-
loxanes derived from MSTFA hydrolyzation were manu-
ally identified and removed from the results table.
Metabolite peak areas were normalized to creatinine. Stu-
dent's t-test was performed in Microsoft Excel 5.0.
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